Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 11/20 | 0.59 |
| ▸ | IGF1R | P08069 | 9/20 | 0.58 |
| ▸ | INSR | P06213 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3296797 | 0.92 | IGF1R (0.57) | TNK2IGF1R | |
| SCHEMBL3293501 | 0.91 | TNK2 (0.71) | TNK2IGF1RINSR | |
| SCHEMBL3302800 | 0.89 | IGF1R (0.72) | TNK2IGF1R | |
| SCHEMBL3297337 | 0.89 | IGF1R (0.72) | TNK2IGF1R | |
| SCHEMBL3299817 | 0.88 | IGF1R (0.61) | TNK2IGF1R | |
| SCHEMBL3296311 | 0.88 | IGF1R (0.73) | TNK2IGF1R | |
| SCHEMBL3298039 | 0.86 | TNK2 (0.59) | TNK2IGF1RINSR | |
| SCHEMBL3299212 | 0.86 | TNK2 (0.73) | TNK2IGF1R | |
| SCHEMBL3296367 | 0.86 | IGF1R (0.61) | TNK2IGF1R | |
| SCHEMBL3299173 | 0.85 | IGF1R (0.60) | TNK2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741324-B2 | Imidazotriazines as protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | claimed |
| CN-101084218-A | Imidazotriazines as protein kinase inhibitors | OSI PHARM INC (US) | 2007-12-05 | — | — | CN | claimed |
| US-20060019957-A1 | Imidazotriazines as protein kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | claimed |
| US-7741324-B2 | Imidazotriazines as protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| CN-101084218-A | Imidazotriazines as protein kinase inhibitors | OSI PHARM INC (US) | 2007-12-05 | — | — | CN | disclosed |
| US-20060019957-A1 | Imidazotriazines as protein kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019957-A1 | Imidazotriazines as protein kinase inhibitors | IGF1R, IRS1, INSR | TNK2 606/4885IGF1R 1/4885INSR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.